The Biosimilars Market will reach US$50.901 billion in 2030 from US$24.176 billion in 2025 at a CAGR of 16.06% during the forecast period.
Biosimilars are defined as licensed and highly similar versions of biological drugs that have already been approved for use by regulatory bodies. The growth in the market may be attributed to the cost-effectiveness of the biosimilars when compared to reference biologics, coupled with the patent expiration of the many blockbuster biologic drugs. The estimated patent and exclusivity expiry of a few of the blockbuster biologics is given below. Due to the structural complexity of biosimilar drugs, multi-layered manufacturing, and risk of immunogenicity, separate regulatory pathways have been drafted to introduce them into the market.
Biosimilars Market Growth Drivers
The market is propelled by increasing corporate investments in biosimilar development.
Biosimilars Market Regional Insights
Europe dominates the global biosimilars market, driven by the presence of leading biopharmaceutical companies such as Stada, Sandoz, AstraZeneca, and Merck. A well-established regulatory framework for biosimilar approvals, a growing number of product approvals, and advanced healthcare infrastructure further fuel market growth in Europe. North America is also expected to experience significant growth during the forecast period, supported by heightened focus on product development and manufacturers' efforts to capitalize on regional growth opportunities.
Market intelligence is delivered through detailed analysis, charts, and graphics, enabling clients to quickly and effectively understand the global biosimilars market.
The Biosimilars Market Report offers a comprehensive analysis of the industry, providing strategic and executive-level insights backed by data-driven forecasts. This regularly updated report empowers decision-makers with actionable intelligence on market trends, emerging opportunities, and competitive dynamics. Biosimilars are defined as biologic products highly similar to licensed biologic drugs, with minor differences in inactive components. The report also examines technological advancements, key government policies, regulatory frameworks, and macroeconomic factors, delivering a holistic market perspective.
Some of the major players covered in this report include Samsung Bioepis, Stada Arzneimittel AG, Sandoz International GmbH (Novartis), Amgen Inc., Apotex Inc., BioCad, Dr. Reddy's Laboratories Ltd., Biocon, Boehringer Ingelheim International GmbH, Pfizer, BioFactura, and AmerisourceBergen Corporation among others.
What do businesses use our reports for?
Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence
Biosimilars Market Segmentations:
Biosimilars Market Segmentation by Type
The market is analyzed by type into the following:
Biosimilars Market Segmentation by Disease
The market is analyzed by disease into the following:
Biosimilars Market Segmentation by Regions:
The study also analyzed the biosimilars in the following regions, with country-level forecasts and analysis as below:
Biosimilars Market Report Coverage:
This report provides extensive coverage as explained in the points below:
How this report is helpful to you and reasons for the purchase?